Xencor, Inc.
Pitch Summary: Xencor is advancing its bispecific antibody XmAb819 for relapsed/refractory clear cell renal cell carcinoma (ccRCC) and its monospecific anti-TL1A antibody XmAb942 for inflammatory disorders. The company is expected to release preliminary data for XmAb819 in Q4 2025, which could confirm its potential efficacy. Despite a recent stock price decline, Xencor’s innovative XmAb protein […]
